Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

NCT07647263 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

124

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: THP Regimen (Taxane + Trastuzumab + Pertuzumab)
DRUG: Trastuzumab Rezetecan (SHR-A1811)

Sponsor

The First Affiliated Hospital of Soochow University